C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
1.644
-0.106 (-6.07%)
Mar 31, 2025, 1:41 PM EDT - Market open

C4 Therapeutics Statistics

Total Valuation

C4 Therapeutics has a market cap or net worth of $116.69 million. The enterprise value is -$82.95 million.

Market Cap 116.69M
Enterprise Value -82.95M

Important Dates

The next estimated earnings date is Wednesday, May 7, 2025, before market open.

Earnings Date May 7, 2025
Ex-Dividend Date n/a

Share Statistics

C4 Therapeutics has 70.99 million shares outstanding. The number of shares has increased by 39.75% in one year.

Current Share Class 70.99M
Shares Outstanding 70.99M
Shares Change (YoY) +39.75%
Shares Change (QoQ) +1.41%
Owned by Insiders (%) 2.73%
Owned by Institutions (%) 71.98%
Float 47.25M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 3.41
Forward PS 7.47
PB Ratio 0.57
P/TBV Ratio 0.55
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.71, with a Debt / Equity ratio of 0.30.

Current Ratio 5.71
Quick Ratio 5.49
Debt / Equity 0.30
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -45.58% and return on invested capital (ROIC) is -24.46%.

Return on Equity (ROE) -45.58%
Return on Assets (ROA) -20.17%
Return on Invested Capital (ROIC) -24.46%
Return on Capital Employed (ROCE) -38.49%
Revenue Per Employee $323,491
Profits Per Employee -$957,418
Employee Count 110
Asset Turnover 0.10
Inventory Turnover n/a

Taxes

In the past 12 months, C4 Therapeutics has paid $131,000 in taxes.

Income Tax 131,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -78.26% in the last 52 weeks. The beta is 3.00, so C4 Therapeutics's price volatility has been higher than the market average.

Beta (5Y) 3.00
52-Week Price Change -78.26%
50-Day Moving Average 2.86
200-Day Moving Average 4.70
Relative Strength Index (RSI) 26.14
Average Volume (20 Days) 826,082

Short Selling Information

The latest short interest is 8.17 million, so 11.51% of the outstanding shares have been sold short.

Short Interest 8.17M
Short Previous Month 8.55M
Short % of Shares Out 11.51%
Short % of Float 17.30%
Short Ratio (days to cover) 5.80

Income Statement

In the last 12 months, C4 Therapeutics had revenue of $35.58 million and -$105.32 million in losses. Loss per share was -$1.52.

Revenue 35.58M
Gross Profit -75.05M
Operating Income -117.18M
Pretax Income -106.59M
Net Income -105.32M
EBITDA -115.36M
EBIT -117.18M
Loss Per Share -$1.52
Full Income Statement

Balance Sheet

The company has $244.90 million in cash and $65.76 million in debt, giving a net cash position of $201.51 million or $2.84 per share.

Cash & Cash Equivalents 244.90M
Total Debt 65.76M
Net Cash 201.51M
Net Cash Per Share $2.84
Equity (Book Value) 215.99M
Book Value Per Share 3.06
Working Capital 212.59M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$65.16 million and capital expenditures -$180,000, giving a free cash flow of -$65.34 million.

Operating Cash Flow -65.16M
Capital Expenditures -180,000
Free Cash Flow -65.34M
FCF Per Share -$0.92
Full Cash Flow Statement

Margins

Gross margin is -210.92%, with operating and profit margins of -329.30% and -295.96%.

Gross Margin -210.92%
Operating Margin -329.30%
Pretax Margin -295.60%
Profit Margin -295.96%
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

C4 Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -39.75%
Shareholder Yield -39.75%
Earnings Yield -88.83%
FCF Yield -55.11%

Analyst Forecast

The average price target for C4 Therapeutics is $12.50, which is 660.43% higher than the current price. The consensus rating is "Buy".

Price Target $12.50
Price Target Difference 660.43%
Analyst Consensus Buy
Analyst Count 4
Revenue Growth Forecast (5Y) 113.92%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

C4 Therapeutics has an Altman Z-Score of -0.92 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -0.92
Piotroski F-Score 3